In healthcare domain, complication risk profiling which can be seen as multiple clinical risk prediction tasks is challenging due to the complex interaction between heterogeneous clinical entities. With the availability of real-world data, many deep learning methods are proposed for complication risk profiling. However, the existing methods face three open challenges. First, they leverage clinical data from a single view and then lead to suboptimal models. Second, most existing methods lack an effective mechanism to interpret predictions. Third, models learned from clinical data may have inherent pre-existing biases and exhibit discrimination against certain social groups. We then propose a multi-view multi-task network (MuViTaNet) to tackle these issues. MuViTaNet complements patient representation by using a encoder to exploit more information. Moreover, it uses a learning to generate more generalized representations using both labeled and unlabeled datasets. Last, a fairness variant (F-MuViTaNet) is proposed to mitigate the unfairness issues and promote healthcare equity. The experiments show that MuViTaNet outperforms existing methods for cardiac complication profiling. Its architecture also provides an effective mechanism for interpreting the predictions, which helps clinicians discover the underlying mechanism triggering the complication onsets. F-MuViTaNet can also effectively mitigate the unfairness with only negligible impact on accuracy.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10046420 | PMC |
http://dx.doi.org/10.1007/s10115-022-01813-2 | DOI Listing |
Cancer Nurs
January 2025
Author Affiliations: Department Research, Hospital Germans Trias i Pujol, Universitat Autonòma de Barcelona; and NURECARE Research Group, Institut d'Investigació i Hospital Germans Trias i Pujol (IGTP), Ctra de Can Ruti, Camí de les Escoles (Dr Huertas-Zurriaga); Department Research, Institut Català Oncologia-Hospital Germans Trias i Pujol; Universitat Autonòma de Barcelona; GRIN Group, IDIBELL, Institute of Biomedical Research; and NURECARE Research Group, IGTP, Ctra de Can Ruti, Camí de les Escoles (Dr Cabrera-Jaime); Tecnocampus University and NURECARE Research Group, IGTP, Ctra de Can Ruti, Camí de les Escoles (Dr Navarri); Oncology Department, Hereditarian Cancer Program, Institut Català Oncologia-Hospital Germans Trias i Pujol, B-ARGO (Badalona Applied Research Group in Oncology), IGTP (Health Research Institute Germans Trias i Pujol), Universitat Autònoma de Barcelona (Dr Teruel-Garcia); and Nursing Research Group in Vulnerability and Health (GRIVIS); and Nursing Department, Faculty of Medicine, Universitat Autònoma de Barcelona (Dr Leyva-Moral), Badalona, Spain.
Background: Breast cancer survivors face unique challenges in breastfeeding decisions. Limited research exists on the experiences and decision-making processes of young women with breast cancer regarding breastfeeding.
Objective: To explain the decision-making processes of young women with breast cancer in relation to breastfeeding throughout the cancer trajectory.
Minerva Urol Nephrol
January 2025
Department of Urology, The Second Affiliated Hospital of Shantou University Medical College, Shantou, China -
Background: The rising incidence of kidney stones underscores the imperative to devise effective preventive measures. While a robust association between cardiovascular disease (CVD) and kidney stones exists, the current research landscape lacks investigations between cardiovascular health (CVH) and kidney stones. This study aims to explore the association between CVH, assessed by Life's Essential 8 (LE8), and kidney stones, with the role of blood lipids and insulin resistance in this relationship.
View Article and Find Full Text PDFCNS Drugs
January 2025
School of Medicine and Dentistry, Gold Coast Campus, Griffith University, Southport, QLD, 4222, Australia.
Background: Epstein-Barr virus (EBV) is implicated as a necessary factor in the development of multiple sclerosis (MS) and may also be a driver of disease activity. Although it is not clear whether ongoing viral replication is the driver for MS pathology, MS researchers have considered the prospect of using drugs with potential efficacy against EBV in the treatment of MS. We have undertaken scientific and lived experience expert panel reviews to shortlist existing licensed therapies that could be used in later-stage clinical trials in MS.
View Article and Find Full Text PDFOphthalmol Ther
January 2025
International Health Policy Program (IHPP), Ministry of Public Health, Nonthaburi, Thailand.
Introduction: Screening diabetic retinopathy (DR) for timely management can reduce global blindness. Many existing DR screening programs worldwide are non-digital, standalone, and deployed with grading retinal photographs by trained personnel. To integrate the screening programs, with or without artificial intelligence (AI), into hospital information systems to improve their effectiveness, the non-digital workflow must be transformed into digital.
View Article and Find Full Text PDFMol Divers
January 2025
Key Laboratory of Prevention and Treatment of Cardiovascular and Cerebrovascular Diseases Ministry of Education, Jiangxi Province Key Laboratory of Biomaterials and Biofabrication for Tissue Engineering, Gannan Medical University, Ganzhou, 341000, Jiangxi, China.
Identifying drug-target binding affinity (DTA) plays a critical role in early-stage drug discovery. Despite the availability of various existing methods, there are still two limitations. Firstly, sequence-based methods often extract features from fixed length protein sequences, requiring truncation or padding, which can result in information loss or the introduction of unwanted noise.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!